Neuropeptidni Y receptor (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Neuropeptidni Y receptor" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

11nih.gov

4^th place

3^rd place

10doi.org

2^nd place

5bentham-direct.org

low place

5,831^st place

3archive.today

14^th place

30^th place

1aspetjournals.org

6,663^rd place

1,410^th place

archive.today

Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.

aspetjournals.org

pharmrev.aspetjournals.org

Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. ^{[mrtav link]}

bentham-direct.org

Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774. ^{[mrtav link]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213. ^{[mrtav link]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.

doi.org

dx.doi.org

Heilig M (August 2004). „The NPY system in stress, anxiety and depression”. Neuropeptides 38 (4): 213–24. DOI:10.1016/j.npep.2004.05.002. PMID 15337373.
Harro J (October 2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids 31 (3): 215–30. DOI:10.1007/s00726-006-0334-x. PMID 16738800.
Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774. ^{[mrtav link]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213. ^{[mrtav link]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
Lindner D, Stichel J, Beck-Sickinger AG (September 2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. DOI:10.1016/j.nut.2008.06.025. PMID 18725086.
Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides 38 (4): 141–51. DOI:10.1016/j.npep.2004.06.002. PMID 15337367.
Kamiji MM, Inui A (October 2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews 28 (6): 664–84. DOI:10.1210/er.2007-0003. PMID 17785427.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.

nih.gov

ncbi.nlm.nih.gov

Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). „XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors”. Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. ^{[mrtav link]}
Heilig M (August 2004). „The NPY system in stress, anxiety and depression”. Neuropeptides 38 (4): 213–24. DOI:10.1016/j.npep.2004.05.002. PMID 15337373.
Harro J (October 2006). „CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies”. Amino Acids 31 (3): 215–30. DOI:10.1007/s00726-006-0334-x. PMID 16738800.
Eaton K, Sallee FR, Sah R (2007). „Relevance of neuropeptide Y (NPY) in psychiatry”. Current Topics in Medicinal Chemistry 7 (17): 1645–59. DOI:10.2174/156802607782341037. PMID 17979774. ^{[mrtav link]}
Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). „Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide”. Recent Patents on CNS Drug Discovery 1 (3): 315–24. DOI:10.2174/157488906778773689. PMID 18221213. ^{[mrtav link]}
Vona-Davis LC, McFadden DW (2007). „NPY family of hormones: clinical relevance and potential use in gastrointestinal disease”. Current Topics in Medicinal Chemistry 7 (17): 1710–20. DOI:10.2174/156802607782340966. PMID 17979780. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-08-09.
Lindner D, Stichel J, Beck-Sickinger AG (September 2008). „Molecular recognition of the NPY hormone family by their receptors”. Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. DOI:10.1016/j.nut.2008.06.025. PMID 18725086.
Larhammar D, Salaneck E (2004). „Molecular evolution of NPY receptor subtypes”. Neuropeptides 38 (4): 141–51. DOI:10.1016/j.npep.2004.06.002. PMID 15337367.
Kamiji MM, Inui A (October 2007). „Neuropeptide y receptor selective ligands in the treatment of obesity”. Endocrine Reviews 28 (6): 664–84. DOI:10.1210/er.2007-0003. PMID 17785427.
MacNeil DJ (2007). „NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs”. Current Topics in Medicinal Chemistry 7 (17): 1721–33. DOI:10.2174/156802607782341028. PMID 17979781. Arhivirano iz originala na datum 2013-01-12. Pristupljeno 2021-10-05.
Kamiji MM, Inui A (2007). „NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?”. Current Topics in Medicinal Chemistry 7 (17): 1734–42. DOI:10.2174/156802607782340957. PMID 17979782. Arhivirano iz originala na datum 2013-04-14. Pristupljeno 2021-10-05.